用雷帕霉素靶蛋白（mTOR）抑制剂靶向神经节神经瘤。
Targeting ganglioneuromas with mTOR inhibitors.
作者信息
Tao Ting, Shi Hui, Durbin Adam D, Look A Thomas
机构信息
Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Children's Regional Medical Center, Hangzhou, China.
Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
出版信息
Mol Cell Oncol. 2021 Jan 10;8(1):1856621. doi: 10.1080/23723556.2020.1856621.
We recently identified activated protein kinase B (PKB/AKT) as a tumorigenic driver in childhood ganglioneuroma. Inhibition of the mechanistic target of rapamycin (mTOR), a serine/threonine kinase downstream of AKT, effectively reduced the tumor burden in zebrafish with ganglioneuroma. We propose a clinical trial of mTOR inhibitors as a means to shrink large ganglioneuromas prior to surgical resection.
我们最近确定活化蛋白激酶B（PKB/AKT）是儿童神经节神经瘤的致瘤驱动因素。雷帕霉素作用靶点（mTOR）是AKT下游的一种丝氨酸/苏氨酸激酶，抑制该激酶可有效减轻患有神经节神经瘤的斑马鱼的肿瘤负担。我们提议开展一项关于mTOR抑制剂的临床试验，作为在手术切除前缩小大型神经节神经瘤的一种方法。
Zotero 插件